Top GLP-1 & Obesity Drug Stocks

GLP-1 stocks are shares in pharmaceutical companies developing or manufacturing GLP-1 receptor agonist drugs — the class of medications that includes Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs treat obesity, type 2 diabetes, and increasingly, cardiovascular and metabolic conditions.

Both LLY and NVO are leading GLP-1 stocks. Lilly's tirzepatide (dual GLP-1/GIP agonist) demonstrates superior weight loss efficacy. Novo Nordisk's semaglutide has a longer commercial track record and broader cardiovascular outcome data. Valuation, pipeline depth, and manufacturing capacity are key differentiators.

Major investment banks and healthcare analysts project the GLP-1 market could reach $130–150B+ in annual revenue by 2030, driven by obesity, type 2 diabetes, and expanding cardiovascular indications. Oral GLP-1 formulations from Eli Lilly, Novo Nordisk, and others could dramatically expand the addressable patient population beyond injectable-tolerant patients, potentially pushing total market estimates higher than current projections.

Beyond Eli Lilly and Novo Nordisk, the most tracked obesity drug stocks include Amgen (AMGN) for MariTide — a differentiated monthly GLP-1/GIPR antagonist in Phase 3 — and Regeneron (REGN) for its bispecific antibody program targeting obesity pathways. Dexcom (DXCM) is an obesity infrastructure play as continuous glucose monitoring expands alongside GLP-1 prescription growth. Viking Therapeutics (VKTX) is a higher-risk, earlier-stage pipeline name frequently discussed but not included here due to its speculative stage.

Semaglutide (Ozempic/Wegovy) is protected by patents that expire in the early-to-mid 2030s in major markets, with Novo Nordisk filing continuation patents on formulations and delivery mechanisms. Tirzepatide (Mounjaro/Zepbound) has a similar multi-year patent runway. Generic GLP-1 peptides are also technically complex to manufacture as biologics — biosimilar entry is more likely than traditional small-molecule generics, but biosimilar development for injectable GLP-1s requires significant investment and is years away from material market impact.

Pfizer's danuglipron — an oral GLP-1 receptor agonist — failed its Phase 3 clinical program due to tolerability issues, primarily nausea and vomiting at doses required for therapeutic weight loss. The failure reinforced the challenge of oral GLP-1 formulation: achieving sufficient drug exposure to drive weight loss with acceptable side effects at doses patients tolerate. Eli Lilly's orforglipron and Novo Nordisk's oral semaglutide (Rybelsus) have demonstrated more favorable tolerability profiles, keeping the oral GLP-1 opportunity alive despite Pfizer's exit.

The GLP-1 investment theme has multi-decade tailwinds: obesity affects 1B+ people globally, existing market penetration is low, new indications (cardiovascular, kidney, liver, Alzheimer's) are expanding the addressable patient population, and oral formulations could broaden access significantly. The primary risks are valuation (LLY and NVO trade at large premiums to the S&P 500), insurance coverage gaps limiting US penetration, and the possibility that next-generation therapies (AMG133, bispecifics, orals from multiple companies) commoditize the category. For long-term investors comfortable with premium healthcare valuations, GLP-1 remains one of the most durable pharmaceutical themes of the decade.

Yes — both companies now have FDA-approved oral GLP-1 pills. Eli Lilly's Foundayo (orforglipron) was approved in April 2026 as the first GLP-1 obesity pill with no food or water restrictions, with its ATTAIN-1 trial showing more than 12% average body weight loss at the highest dose. Novo Nordisk's oral Wegovy pill was also FDA-approved, backed by OASIS 4 data showing up to 16.6% mean weight loss, though it carries the dosing restrictions typical of oral semaglutide. Removing the injection barrier is expected to significantly expand the addressable GLP-1 patient population beyond those willing to self-inject.

Starting July 1, 2026, Medicare began covering GLP-1 drugs for weight loss for eligible seniors at a $50 per month cost, extending coverage that was previously limited mostly to diabetes and cardiovascular indications. This is a meaningful catalyst for GLP-1 prescription volume growth, since Medicare beneficiaries represent a large share of the obesity and cardiometabolic disease population that had previously faced high out-of-pocket costs.